“…The NS2B/NS3 protease is a particularly promising flavivirus therapeutic target, with extensive research on development of inhibitors as therapeutic candidates. Various strategies for Dengue NS2B/NS3 inhibitor development were recently reviewed (Luo et al, 2015), including design of both peptidic (Prusis et al, 2013; Xu et al, 2012) and non-peptidic small molecule inhibitors (Cabarcas-Montalvo et al, 2016; Chu et al, 2015; Deng et al, 2012; Lai et al, 2013a; Lai et al, 2013b; Li et al, 2015; Liu et al, 2014; Tomlinson and Watowich, 2011; Viswanathan et al, 2014; Wu et al, 2015; Zhou et al, 2013). There are already indications that resistance against protease inhibitors develops readily (Yang et al, 2011; Yang et al, 2014), consistent with the HCV protease inhibitor experience (Romano et al, 2010).…”